LU77240A1 - - Google Patents

Info

Publication number
LU77240A1
LU77240A1 LU77240A LU77240A LU77240A1 LU 77240 A1 LU77240 A1 LU 77240A1 LU 77240 A LU77240 A LU 77240A LU 77240 A LU77240 A LU 77240A LU 77240 A1 LU77240 A1 LU 77240A1
Authority
LU
Luxembourg
Application number
LU77240A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7612942A external-priority patent/FR2349328A1/fr
Priority claimed from FR7701299A external-priority patent/FR2377395A2/fr
Application filed filed Critical
Publication of LU77240A1 publication Critical patent/LU77240A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU77240A 1976-04-30 1977-05-03 LU77240A1 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7612942A FR2349328A1 (fr) 1976-04-30 1976-04-30 Nouveaux derives de la 11-desoxy prostaglandine f2, leur procede de preparation et leur application comme medicaments
FR7701299A FR2377395A2 (fr) 1977-01-18 1977-01-18 Nouveaux derives de la 11-desoxy prostaglandine f2, leur procede de preparation et leur application comme medicaments

Publications (1)

Publication Number Publication Date
LU77240A1 true LU77240A1 (sv) 1977-12-13

Family

ID=26219428

Family Applications (1)

Application Number Title Priority Date Filing Date
LU77240A LU77240A1 (sv) 1976-04-30 1977-05-03

Country Status (14)

Country Link
US (1) US4119727A (sv)
JP (1) JPS52148048A (sv)
AR (1) AR222627A1 (sv)
AT (1) AT355739B (sv)
AU (1) AU511408B2 (sv)
CA (1) CA1100493A (sv)
CH (1) CH620675A5 (sv)
DE (1) DE2719244A1 (sv)
DK (1) DK187677A (sv)
GB (1) GB1538842A (sv)
IE (1) IE45141B1 (sv)
LU (1) LU77240A1 (sv)
NL (1) NL7704758A (sv)
SE (1) SE436037B (sv)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0282901U (sv) * 1988-12-12 1990-06-27
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US20050203081A1 (en) * 2004-02-25 2005-09-15 Jinbo Lee Inhibitors of protein tyrosine phosphatase 1B
US7521473B2 (en) 2004-02-25 2009-04-21 Wyeth Inhibitors of protein tyrosine phosphatase 1B
US7906552B2 (en) 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7183310B2 (en) 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
AU2006205029B2 (en) * 2005-01-14 2012-09-06 Allergan, Inc. Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
TW201410248A (zh) * 2005-03-04 2014-03-16 Sucampo Ag 處理週邊血管疾患之方法及組成物
AU2006311942B2 (en) 2005-11-03 2012-11-22 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
CA2724271A1 (en) * 2008-05-15 2009-11-19 Allergan, Inc. Therapeutic substituted cyclopentanes
EP2923756B1 (en) 2012-11-26 2018-05-30 Braskem S.A. Metallocene catalyst supported by hybrid supporting means, process for producing same, polymerization process for producing an ethylene homopolymer or copolymer with broad or bimodal molar mass distribution, use of the supported metallocene catalyst and ethylene polymer with broad or bimodal molar mass distribution

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776940A (en) * 1966-08-09 1973-12-04 G Just Intermediates for producing prostaglandins
US3956284A (en) * 1972-07-13 1976-05-11 Pfizer Inc. Heterocyclic 15-substituted-ω-pentanorprostoglandins
US3794664A (en) * 1972-08-17 1974-02-26 G Just Bicyclo(3.1.0)hexane intermediates for producing prostaglandins f1alpha and f1beta
US4387241A (en) * 1974-11-01 1983-06-07 American Cyanamid Company Novel 16-aryloxy-17,18,19,20-tetranorprostanoic acids and derivatives

Also Published As

Publication number Publication date
AT355739B (de) 1980-03-25
ATA310177A (de) 1979-08-15
DE2719244A1 (de) 1977-11-17
IE45141L (en) 1977-10-30
AU2479577A (en) 1978-11-09
DE2719244C2 (sv) 1987-10-15
DK187677A (da) 1977-10-31
NL7704758A (nl) 1977-11-01
CH620675A5 (sv) 1980-12-15
IE45141B1 (en) 1982-06-30
SE436037B (sv) 1984-11-05
JPS6131103B2 (sv) 1986-07-17
AR222627A1 (es) 1981-06-15
CA1100493A (fr) 1981-05-05
GB1538842A (en) 1979-01-24
US4119727A (en) 1978-10-10
AU511408B2 (en) 1980-08-21
SE7704616L (sv) 1977-10-31
JPS52148048A (en) 1977-12-08

Similar Documents

Publication Publication Date Title
DE2704841C2 (sv)
FR2370477B1 (sv)
FR2336886B1 (sv)
FI770115A (sv)
FI763759A (sv)
DE2743284C2 (sv)
DK129676A (sv)
DK142263C (sv)
DK142288C (sv)
FI770240A (sv)
FI53559B (sv)
DK141181C (sv)
FR2349328B1 (sv)
JPS5537029Y2 (sv)
DE2628048C2 (sv)
JPS5632255Y2 (sv)
JPS5310934U (sv)
JPS52120269U (sv)
FI52685B (sv)
DK138871C (sv)
JPS52105314U (sv)
JPS5356046U (sv)
JPS52166360U (sv)
JPS51155801U (sv)
DK561176A (sv)